TGA AI Scribe Guidance: When a Tool Suggests Care
Outline
A feature change at a fictional visit
Your fictional client Morgan describes difficulty sleeping. You discuss sleep routines, but no diagnosis. Your practice has already approved the existing documentation function; the supplier proposes a new feature.
| Supplier description | Intended purpose | Enabled function |
|---|---|---|
| ”Organizes what the psychologist said” | Document the visit | Organize stated content |
| ”Suggests a diagnosis not discussed” | Ask supplier to specify | Generate a diagnosis suggestion |
Ask for the supplier’s written classification rationale and intended purpose for the exact version and each function, plus any applicable Australian Register of Therapeutic Goods (ARTG) entry or exemption basis. Defer the new function while evidence is missing. A single anomalous output is not enough to classify the product.
For your already authorized documentation workflow, compare the draft against what you actually said: if it says you discussed a diagnosis, remove that unsupported statement. Sign only the record you have reviewed.
Record the feature decision
Use the Scribe Feature Change: Intended-Use Comparison sheet in the AI Scribe Governance Sheets for Australia, the UK, Canada and New Zealand to record your evidence, unresolved questions and decision.
Document your scribe feature decision
Use the comparison sheet this week to record your decision and the evidence behind it.
- Client Recorder Request and Response Card and Scribe Feature Change: Intended-Use Comparison
- Changed Scribe: Australian Choice Preparation Sheet for planning the discussion and separate signed record
- England Scribe Error Trace and Follow-Up Sheet and Ontario RP AI-Assistance Attribution Card
- NZ Ambient Note: Observation Add-Back Card
Free. We'll email the PDF link right away and add you to the therapist toolkit, sent every two weeks. Unsubscribe any time.
Where should we send the link?
We'll email the PDF link right away. You'll also get the therapist toolkit every two weeks. Unsubscribe any time.
✓ Check your inbox
We've sent you the PDF
The download link is on its way to your inbox, usually within a minute or two. The email will come from Emosapien (hello@team.emosapien.com); check your spam folder if you don't see it.
You're also on the therapist toolkit list, sent every two weeks. Unsubscribe any time from the email footer.
TGA AI scribe guidance: intended purpose and output
You are deciding whether to enable a function, not whether an attractive draft looks useful. Write down the previous approved purpose and version, the supplier’s new claim, the exact setting you would enable and who can use it. Ask the supplier to identify the intended purpose of each function, including any function that generates suggestions for an individual client. Compare the answer with the instructions, marketing and functionality presented to users.
The Therapeutic Goods Administration’s Digital scribes guidance, checked November 2026, distinguishes administrative functions from software with a therapeutic purpose. For your TGA AI scribe decision, it says a scribe intended only to record, transcribe or organize a conversation without adding clinical suggestions not explicitly stated by the practitioner is not considered a medical device. Software intended to suggest diagnoses or treatments is likely to be a medical device. A product can contain both device and non-device functions, and a summary feature can still be regulated if the manufacturer’s intended-purpose claims extend to diagnosis or treatment.
The distinction is not settled by the name “scribe,” a supplier badge, a disclaimer, or the fact that you review the output. A surprising output deserves investigation, but one output alone does not establish regulatory classification. If you cannot reconcile the written claims, enabled functionality and evidence, defer the change and confirm with the TGA.
Ask the supplier to distinguish an intended recommendation from an unintended generation error. Keep the example in a secure practice record without relying on it as the whole classification analysis. Check whether the function is enabled by default, who can change the setting and whether the supplier describes the same purpose in its instructions and product materials. If the descriptions conflict, request a written explanation tied to the version your practice would use.
You can read how Emosapien works when considering a documentation workflow.
Ask for the regulatory and privacy evidence
For the version and function proposed, request the supplier’s written classification rationale and, if applicable, the ARTG entry or exemption basis. The TGA says medical devices must meet relevant requirements and be included in the ARTG before supply unless exempt. An exemption is not proof that the software falls outside medical-device regulation. If the supplier relies on an exemption, ask which basis and conditions it applies and how the proposed version meets them. Confirm unresolved questions with the TGA instead of accepting a badge as a decision.
When you receive an ARTG entry, check that its manufacturer and product details correspond to the product and version your practice intends to use. Ask the supplier to explain any mismatch rather than treating a similar product name as confirmation. Keep the entry or the supplier’s written explanation with the feature decision.
If the supplier provides a broad assurance but no function-specific rationale, ask which of your enabled functions are covered and whether an update changes what the product is intended to do. A response about an older version or a different configuration may not answer your question. Record the specific version and setting in your request so the supplier can address your proposed use. Identify the gap in your approval record and retain the defer decision until you have the evidence you need.
Before client information enters a new function, ask what information it receives, who can access it, where it is processed, how long it is retained and how it is deleted. Give your privacy lead the supplier’s written answers and check the obligations that apply to your practice. Discuss the proposed use and available alternative with the client under your informed-consent process. For the separate consent decision, use the Australian scribe consent guide.
For a documentation workflow you have already authorized, see how notes are drafted and reviewed. Check the proposed wording against the session, correct omissions or additions, and sign only the reviewed record. Your review is a clinical-record safeguard, not a way to establish device status. Ask your supplier for evidence about local data handling and any other requirement that affects your decision.
Keep the TGA AI scribe decision on file
Record the previously approved purpose and version; the new supplier claim and an example of added content; the written intended purpose and evidence requested; any applicable ARTG entry or exemption basis and unresolved questions; and your decision to defer, escalate or retain the existing workflow, with the reviewer’s name. Keep supplier correspondence and the version or setting it addresses with your practice’s approval record. Reassess when the supplier changes the enabled function or its claims. Do not send client details through the email-only form.
If you retain the existing workflow, specify which setting remains approved and who can authorize a later change. Record the date you requested missing evidence and the person responsible for following up. If an update automatically enables the proposed feature, check whether you can disable it before continuing the previously approved workflow. If you cannot establish that boundary, pause and escalate to your practice lead rather than assuming the old approval covers the update. Keep the decision and the supplier’s response together so the next reviewer can see what was and was not resolved.
This is an educational practice aid, not legal advice. Confirm unresolved regulatory questions with the TGA and consult your practice’s privacy or legal adviser about your circumstances.
Review and sign every note yourself
If you are considering a separate documentation workflow, Emosapien’s Scribe Agent drafts a note from the session for you to review, edit and sign. Its Safety and Compliance Agent supports consent management and audit logging. Emosapien does not determine another supplier’s TGA status or replace the supplier’s regulatory evidence or confirmation with the TGA. Ask each supplier for the evidence relevant to the functions you plan to use.
Review the documented visit before signing it
Keep your clinical review central to every note.
Start reviewing- Clinician sign-off
- SOC 2 Type II audited infrastructure
Session detail
We discussed sleep routines.
Clinician review
Check the draft against the visit before signing.
References
- Therapeutic Goods Administration, Digital scribes, checked November 2026.
Related reading
ACA AI Recommendations: Test a Tool Before Client Use
Apply ACA AI recommendations to a fictional three-case acceptance test of a check-in prompt writer before considering client use.
Read article →ACA Ethical Codes: Principles and Section-by-Section Practice Guide
Use the ACA ethical codes as a practice guide. Match each ACA Code of Ethics section to the counseling decision in front of you.
Read article →Free PDF: AI Scribe Governance Sheets for Australia, the UK, Canada and New Zealand
Six printable sheets for documenting recorder requests, changed scribe choices, feature decisions, note errors, AI attribution, and observation review.
- Client Recorder Request and Response Card and Scribe Feature Change: Intended-Use Comparison
- Changed Scribe: Australian Choice Preparation Sheet for planning the discussion and separate signed record
- England Scribe Error Trace and Follow-Up Sheet and Ontario RP AI-Assistance Attribution Card
- NZ Ambient Note: Observation Add-Back Card
Free. We'll email the PDF link right away and add you to the therapist toolkit, sent every two weeks. Unsubscribe any time.
Where should we send the link?
We'll email the PDF link right away. You'll also get the therapist toolkit every two weeks. Unsubscribe any time.
✓ Check your inbox
We've sent you the PDF
The download link is on its way to your inbox, usually within a minute or two. The email will come from Emosapien (hello@team.emosapien.com); check your spam folder if you don't see it.
You're also on the therapist toolkit list, sent every two weeks. Unsubscribe any time from the email footer.